Seattle biotech company Kineta is betting that a toxin from a Caribbean Sea anemone can stop autoimmune diseases, including type 1 diabetes and multiple sclerosis.
The compound shows promise in animals. But in a tough market, where does a small startup find the kind of money and patience to support lengthy clinical trials to determine whether it works in humans?... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1397